Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Artery Stenosis Drug Market Forecast: What Value Will The Market Reach By 2030?
The artery stenosis drug market size has experienced significant expansion in recent years. This market is projected to expand from $2.6 billion in 2025 to $2.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. Historically, this growth has been influenced by factors such as the prevalence of cardiovascular disease, the increasing aging population, the adoption of statin therapy, the incidence of hypertension, and the expansion of hospital cardiology departments.
The market for artery stenosis drugs is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $3.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This projected increase can be ascribed to several factors, including a greater emphasis on preventive cardiology, the implementation of early diagnosis initiatives, an increase in combination therapy adoption, improved chronic disease management, and expanded outpatient cardiovascular care. Key developments during this period are expected to involve a growing reliance on combination cardiovascular therapies, a wider embrace of preventive drug regimens, an increase in long-term statin use, the broadening of vascular care for the elderly, and a heightened focus on preventing strokes and heart attacks.
Get A Free Sample Report With In-Depth Market Insights:
Artery Stenosis Drug Market Growth Factors Behind Sustained Expansion
The increasing incidence of diabetes and obesity is anticipated to drive the expansion of the artery stenosis drug market in the future. Diabetes is a chronic ailment characterized by inadequate insulin production or inefficient insulin utilization by the body, leading to high blood sugar; conversely, obesity is a medical state defined by excessive body fat, which heightens the risk of various health complications. The surge in these conditions, diabetes and obesity, is exacerbated by insufficient physical activity, often linked to more sedentary work settings and leisure pursuits involving screens, both of which contribute to weight accumulation and insulin resistance. Artery stenosis medications become essential in cases of diabetes and obesity because both illnesses encourage the formation of plaque within arteries, thereby elevating the danger of heart attacks and strokes. For example, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported 2.0 million diabetes-related deaths in September 2023. Consequently, the expanding prevalence of diabetes and obesity is stimulating growth within the artery stenosis drug market.
Artery Stenosis Drug Market Segmentation And Category Overview
The artery stenosis drug market covered in this report is segmented –
1) By Drug Type: Antiplatelet Agents, Anticoagulants, Statins, Beta Blockers
2) By Mechanism Of Action: Platelet Aggregation Inhibitors, Thrombin Inhibitors, HMG-CoA Reductase Inhibitors, Beta-Adrenergic Antagonists
3) By Route Of Administration: Oral, Injectable, Transdermal
4) By Patient Type: Adults, Geriatric, Pediatric
Subsegments:
1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamole
2) By Anticoagulants: Warfarin, Heparin, Low Molecular Weight Heparins, Direct Oral Anticoagulants (DOACs)
3) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Lovastatin
4) By Beta Blockers: Metoprolol, Atenolol, Propranolol, Carvedilol, Bisoprolol
Artery Stenosis Drug Market Industry Trends Fueling Future Revenue Growth
Leading companies in the artery stenosis drug market are dedicated to advancing therapeutic innovations, such as sirolimus drug-coated balloons, to address critical medical needs in peripheral artery disease treatment. These sirolimus drug-coated balloons are medical devices that integrate balloon angioplasty with targeted drug delivery, releasing sirolimus, an antiproliferative agent, directly into the arterial wall during inflation to prevent restenosis and improve long-term vessel patency. For instance, in November 2024, Cordis Corporation, a US-based cardiovascular medical device company, reported positive 24-month results from the Selution SFA Japan trial, highlighting the effectiveness of its Selution SLR sirolimus drug-coated balloon in treating superficial femoral artery disease. The data revealed a primary patency rate of 86.8% at 24 months and a low target lesion revascularization rate of 6.6%, demonstrating sustained vessel openness and a reduced need for repeat interventions. The Selution SLR balloon ensures a continuous and controlled release of sirolimus to the arterial wall, thereby inhibiting excessive tissue growth that leads to re-narrowing, while also maintaining excellent safety profiles for patients with peripheral artery stenosis.
Artery Stenosis Drug Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the artery stenosis drug market are Pfizer Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Sanofi S.A., Merck & Co. Inc., Johnson & Johnson Services Inc., GSK plc, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited
View The Full Artery Stenosis Drug Market Report:
Artery Stenosis Drug Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the artery stenosis drug market in 2025. The regions covered in the artery stenosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
